Antifungal prophylaxis with azoles is considered standard in allogeneic hematopoietic SCT (allo-HSCT). Although sirolimus is being used increasingly for the prevention of GVHD, it is a substrate of CYP3A4, which is inhibited by voriconazole, and concurrent administration can lead to significantly increased exposure to sirolimus. We identified 67 patients with hematologic malignancies who underwent allo-HSCT with sirolimus, tacrolimus and low-dose MTX and received concomitant voriconazole prophylaxis from April 2008 to June 2011. All patients underwent a non-myeloablative or reduced-intensity conditioned allo-HSCT. Patients received sirolimus and voriconazole concurrently for a median of 113 days. The median daily dose reduction of sirolimus at the start of coadministration was 90%. The median serum sirolimus trough levels before and at steady state of coadministration were 5.8 ng/mL (range: 0-47.6) and 6.1 ng/mL (range: 1-14.2) (P = 0.45), respectively. One patient with an average sirolimus level of 6 ng/mL developed sirolimus-related thrombotic microangiopathy that resolved after sirolimus discontinuation. No sinusoidal obstructive syndrome was reported. Seventeen patients (25%) prematurely discontinued voriconazole because of the adverse events. Only two patients (3%) presented with possible invasive fungal infections at day 100. We demonstrate that sirolimus and voriconazole coadministration with an empiric 90% sirolimus dose reduction and close monitoring of sirolimus trough levels is safe and well tolerated.
INTRODUCTION
Invasive fungal infections (IFIs) remain significant cause of morbidity and mortality after allogeneic hematopoietic SCT (allo-HSCT), 1, 2 and antifungal prophylaxis with azoles is considered standard in allo-HSCT. The epidemiology of IFIs has changed in the last two decades, 3, 4 and recent data show that 60-70% of IFIs in HSCT patients are caused by invasive Aspergillus. 2, 5, 6 Voriconazole has a broad in vitro spectrum against yeast and moulds and is used for fungal prophylaxis after allo-HSCT. [7] [8] [9] Sirolimus, an mTOR inhibitor that was initially developed as an antifungal agent, 10 is increasingly used for the prevention of GVHD. [11] [12] [13] [14] However, there are significant drug interactions between voriconazole and sirolimus. Voriconazole is a substrate and inhibitor of cytochrome P450 (CYP) 2C19 (CYP2C19), CYP2C9 and CYP3A4 isoenzymes, 15 and tacrolimus and sirolimus are both substrates of CYP3A4. Concomitant use with voriconazole can lead to significantly increased exposure to these drugs and contribute to the increased adverse events. 16, 17 Data on sirolimus and voriconazole coadministration are scarce, 18, 19 and the manufacturer of voriconazole contraindicates coadministration with sirolimus given reports that this can lead to significantly increased systemic exposure to sirolimus (product information: Vfend, Pfizer, New York, NY, USA). We now report our results in 67 patients who were treated with both the drugs and demonstrate that coadministration of sirolimus and voriconazole with an empiric 90% dose reduction of sirolimus and close monitoring of sirolimus trough levels is safe and well tolerated.
PATIENTS AND METHODS

Patient characteristics
Sixty-seven consecutive patients with hematologic malignancies received voriconazole prophylaxis after a non-myeloablative or reduced-intensity conditioning allo-HSCT with the combination of sirolimus/tacrolimus with low-dose MTX for GVHD prophylaxis at a single institution (Memorial Sloan Kettering Cancer Center) between April 2008 and June 2011. Patients were included if they received at least one dose of voriconazole and sirolimus concurrently for 41 day. Sixty-one of the patients in this study were included in our recent report that specifically looked at GVHD outcomes in patients who received tacrolimus, sirolimus and mini-MTX as GVHD prophylaxis.
14 Written informed consent for the treatment was obtained from all patients. Approval for this retrospective review was obtained from the Institutional Review and Privacy Board.
Transplant procedure and supportive care
All patients received a lower-intensity conditioning regimen categorized as reduced-intensity conditioning or non-myeloablative using established consensus criteria. 20 GVHD prophylaxis consisted of sirolimus and tacrolimus that were started on day − 3, followed by MTX 5 mg/m 2 on days +1, 3, 6. Doses were adjusted to maintain the target serum trough levels of 3-12 ng/mL and 5-10 ng/mL for sirolimus and tacrolimus, respectively. Recipients of matched unrelated donar (n = 26) or mismatched unrelated donor (n = 8) grafts were given two and three doses, respectively, of anti-thymocyte globulin. All patients received supportive care and prophylaxis against opportunistic infections in accordance with standard guidelines. Patients remained on micafungin (150 mg/day) during the cytoreduction and until voriconazole initiation, which typically occurred in the first week after HSCT. Voriconazole was administered i.v. 1 at a dose of 6 mg/kg every 12 h for two doses, then 4 mg/kg every 12 h, followed by oral voriconazole 200 mg every 12 h until at least day +75 or cessation of intensive immunosuppression. This antifungal prophylaxis is the standard treatment for all recipients of allografts at our center, regardless of baseline risk for IFI. Patients with GVHD or on corticosteroids therapy also received voriconazole until discontinuation of immunosuppression. Patients with a history of intolerance to voriconazole or a prior IFI resistant to voriconazole, received alternative antifungal prophylaxis (micafungin and/or posaconazole) and were excluded from the analysis. Sirolimus and tacrolimus doses were reduced by 90% and 67%, respectively, when voriconazole was initiated. Trough sirolimus and tacrolimus levels were measured daily starting day -1 and then at least weekly once a therapeutic level was achieved. There was no routine drug monitoring of voriconazole.
Data collection
Analyses were performed as of 31 December 2011. Sirolimus and tacrolimus doses before voriconazole initiation, dose adjustment at the time of voriconazole initiation, and the steady-state dose during coadministration were captured from day 0 to day 28 after transplant. Levels that were clearly documented as being obtained inadvertently after administration of the drug (peak levels) were excluded from the analysis. Any concomitant medications that might interact with sirolimus, tacrolimus or voriconazole were recorded. Measurements of aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase, serum creatinine and QT intervals were recorded at baseline and during coadministration of voriconazole and sirolimus. Aspartate aminotransferase, alanine aminotransferase or alkaline phosphatase levels 43 times the upper limit of normal or 43 times baseline if abnormal at baseline were considered clinically significant. Acute renal failure was defined as serum creatinine concentration 42 mg/dL or a 50% increase in serum creatinine if the baseline value was abnormal. Clinical diagnosis of post-transplant thrombotic microangiopathy was established according to the previously defined international criteria. 21 GVHD was diagnosed clinically, confirmed pathologically whenever possible, and classified according to the standard criteria. 22 Patients who engrafted were evaluable for acute GVHD.
IFI risk stratification and diagnosis
Patients with recent neutropenia (o0.5 × 10 9 neutrophils/L for 410 days), prior history of IFI, prolonged the use of steroids (minimum dose of 0.3 mg/ kg/day of prednisone or equivalent for 43 weeks), treatment with other T-cell immunosuppressants (alemtuzumab, nucleoside analogs) during the past 90 days, were considered as high risk for IFI pre-HSCT. 23 The revised definition of IFI was used as proposed by the Cooperative Group of the European Organization for Research and Treatment of Cancer and Mycoses Study Group of the National Institute of Allergy and Infectious Diseases (EORTC/MSG). 24 
Statistical analysis
Descriptive statistics were used to summarize patient characteristics and safety outcomes. A Wilcoxon signed-rank test was used to compare sirolimus and tacrolimus trough levels before and during voriconazole coadministration to account for the paired observations. Similarly, the difference between baseline aspartate aminotransferase, alanine aminotransferase, alkaline phosphatase and serum creatinine values and peak values during voriconazole coadministration were compared using the signed-rank test and graphically displayed using boxplots. A lowess local regression curve was used to visualize the trend of sirolimus concentrations from the time of transplant to day 28. The incidence of acute GVHD was estimated using the cumulative incidence function, treating relapse and death unrelated to GVHD as competing events. All statistical analyses were done in R (version 2.13.2) (R Foundation for Statistical Computing, Vienna, Austria).
RESULTS
Patient characteristics
Patient characteristics are shown in Table 1 . The median age at transplant was 52 years (range: 23-69 years). The majority of patients were treated for lymphoid malignancies, with 61% of the patients having non-Hodgkin's lymphoma. Conditioning regimen was non-myeloablative in 52 patients (78%) and reduced-intensity conditioning in 15 patients (22%). All patients except one received PBSCs. Twenty-six patients (39%) received a transplant from an HLA-identical sibling donor, whereas the remaining 41 patients received unrelated donor transplantation (10/10 matched in 33 patients and 9/10 matched in 8 patients). Ninety percent of patients were considered at low risk for IFI pre-HSCT.
Study drugs and coadministration parameters Sirolimus and voriconazole treatment characteristics are summarized in Table 2 . All patients received voriconazole for IFI prophylaxis and sirolimus for GVHD prophylaxis. The median day of voriconazole initiation was 8 days after HSCT (range: 2-27 days). Patients received voriconazole concurrently with tacrolimus and sirolimus for a median of 113 days (interquartile range, 13-35; range: 4-1342).
At voriconazole initiation, the daily dose of sirolimus was empirically reduced by a median of 90% (range: 80-92). By the time of the steady state of coadministration, the dose of sirolimus had been reduced by a median of 84% (range: 0-100) from the originally administered dose. Twenty-two patients (33%) required an increase of the sirolimus dose after the initial dose reduction. The median daily dose of sirolimus before voriconazole initiation was 4.6 mg (range: 1-12 mg), with 91% of the patients receiving a sirolimus dose ⩾ 4 mg/day. The median sirolimus doses at start of coadministration and at steady state were 0.5 mg (range: 0.1-1.2 mg) and 0.6 mg (range: 0-2 mg), respectively. The median serum sirolimus trough level before voriconazole coadministration Voriconazole and sirolimus coadministration I Ceberio et al was 5.8 ng/mL (range: 0-47.6 ng/mL), which was not different from the level at steady sate of coadministration (6.1 ng/mL, range 1-14.2 ng/mL; P = 0.45) ( Table 3a) . The median daily dose reductions of tacrolimus at initiation and steady state of coadministration were 64% (range: 33-100) and 51% (range: 0-100), respectively (Table 3b ). The median daily doses of tacrolimus before, at start and steady state of coadministration were 1.3 mg (range: 0.5-4.7 mg), 0.4 mg (range: 0-2.5 mg) and 0.6 mg (range: 0-5 mg), respectively. The median tacrolimus trough level before voriconazole administration was higher than the level after voriconazole coadministration (10.9 ng/ mL vs 7.4 ng/mL, P o 0.001).
Safety and breakthrough IFI The majority of the patients tolerated sirolimus-voriconazole coadministration well and did not experience sirolimus-related adverse events. A total of 838 sirolimus blood levels were drawn over the study period (median 12/patient; range, 9-21). The sirolimus blood levels were relatively stable within the therapeutic range (3-12 ng/mL): 40 measurements (4.8%) from 24 patients were sub-therapeutic and 52 measurements (6.2%) from 17 patients were above the therapeutic target, occurring early in the course of prophylaxis (Figure 1 ). Clinically significant changes in the median serum creatinine levels and liver function tests, when baseline values were compared with peak values during voriconazole coadministration (Figure 2 ), were noted in a minority of patients. The median serum creatinine was 0.8 mg/dL (range: 0.3-2.3) at baseline, and increased to 1.3 mg/dL (range: 0.7-4.2) at peak values. Seven patients (10%) developed renal toxicity attributable to tacrolimus, four of them requiring modification of the immunosuppressant treatment (tacrolimus to mycophenolate mofetil (MMF) in three and to MMF plus steroids in one, who could not receive full dose MTX). Three of the seven patients with tacrolimus-related renal toxicity had at least one serum level of tacrolimus above 10 ng/mL, but none had a serum level above 15 ng/mL during coadministration. One patient with an average sirolimus level of 6 ng/mL developed sirolimus-related thrombotic microangiopathy that resolved after changing the immunosuppression regimen (MMF instead of sirolimus). An additional four patients had at least a doubling of their baseline creatinine with a peak serum creatinine that ranged from 1.5 to 2.0 mg/dL at peak level. These patients were able to continue on their planned prophylaxis. Overall, 14 patients (21%) developed clinically significant hepatotoxicity while on voriconazole prophylaxis. No cases of SOS were observed.
Seventeen patients (25%) prematurely discontinued voriconazole after a median of 28 days (range: 8-51 days) because of adverse events: ten (15%) had elevated liver function tests (12% clinically significant), two (3%) QT interval prolongation, two (3%) visual disturbances, one (1.5%) rash and two (3%) other adverse events.
One patient with low risk for IFI pre-HSCT and one with high risk presented with possible IFI at day 100. The first patient was being treated with steroids for GVHD and was diagnosed with IFI while on micafungin due to intolerance to azoles.
GVHD
The cumulative incidence (95%) of grade 2-4 acute GVHD at day 100 was 0.134 (0.066, 0.228), with one patient developing grade 3 Figure 1 . Scatter plot of all sirolimus concentrations, with a lowess local regression curve (red). The suggested therapeutic range of 3-12 ng/mL and the median concentration is outlined for reference. Voriconazole and sirolimus coadministration I Ceberio et al (skin) and no patients having grade 4. Among the nine patients with acute GVHD before day 100, four received systemic steroids and three were treated with budesonide for grade 2 gastrointestinal GVHD. The other two were treated with topical steroids for skin only GVHD.
DISCUSSION
Despite a label contraindication to sirolimus and voriconazole coadministration and limited data, this combination is increasingly used by clinicians. We now report our experience in 67 patients who received sirolimus and voriconazole concomitantly after allo-HSCT, and show that this combination can be safely used with appropriate adjustments and monitoring. Furthermore, it should be noted that all the patients also received concurrent tacrolimus. A median empirical reduction of sirolimus by 90% and tacrolimus by 64%, and close monitoring of drug concentrations resulted in trough sirolimus and tacrolimus levels similar to those obtained before voriconazole coadministration. The exposure to concomitant sirolimus and voriconazole was prolonged, with a median of 113 days, and was overall well tolerated. None of the 17 patients with an elevated sirolimus trough level (412 ng/mL) had sirolimus-related adverse events. Thrombotic microangiopathy was observed in a single patient, who had therapeutic sirolimus levels at the time, and in whom sirolimus discontinuation led to resolution without further sequelae. No patient developed SOS or sirolimus-related renal toxicity. Seven patients with tacrolimus levels o 15 ng/mL experienced renal insufficiency possibly attributable to tacrolimus. Coadministration of sirolimus and voriconazole was initially contraindicated, based on a study among healthy volunteers showing that oral voriconazole causes an 11-fold increase in the area under the curve and a 7-fold increase in the sirolimus C max . After some case reports of concomitant use of sirolimus and voriconazole in renal transplant recipients, 25, 26 two small series reported safe coadministration in HSCT patients. 18, 19 In the study by Marty et al., 19 11 HSCT recipients were safely treated with voriconazole after an empiric initial 90% sirolimus dose reduction along with the careful monitoring of sirolimus trough levels. Another study of 23 patients, which included 16 HSCT recipients, also reported that sirolimus and voriconazole could be safely coadministered and suggested a dose-reduction strategy based on the baseline sirolimus dose and concentration. 18 The results of our study are consistent with and further expand the results of these prior reports.
A number of reports that have addressed the interactions between tacrolimus and voriconazole, and dose reduction and frequent monitoring of tacrolimus blood concentrations to avoid toxicity are also recommended. [27] [28] [29] [30] All our patients received tacrolimus concomitantly to voriconazole and sirolimus. Tacrolimus and voriconazole coadministration was similarly well tolerated with a median 64% tacrolimus dose reduction at the start of coadministration. None of the seven patients who developed renal toxicity possibly attributed to tacrolimus had tacrolimus levels above 15 ng/mL. The renal toxicity resolved in six out of the seven patients after tacrolimus discontinuation.
Hepatic dysfunction in allo-HSCT recipients is common and may result from various confounding conditions including toxicity from the preparative regimen and other medications, infection and GVHD of the liver. A recent meta-analysis of randomized trials reported that 20% of 881 patients receiving voriconazole experienced an elevation of liver enzymes, and 12% required the cessation of voriconazole. 31 We have previously reported that, in a cohort of 200 patients receiving voriconazole after allo-HSCT, 25% experienced clinically significant elevations in liver enzymes and 17% of patients required voriconazole therapy discontinuation. 32 Consistent with our previous report, in this cohort 12% of the patients developed clinically significant reversible hepatic toxicity, with 15% of the patients requiring cessation of voriconazole. The higher incidence of clinically significant elevation in liver enzymes in the previous study can be explained in part by the use of myeloablative conditioning in 70% of patients in that cohort.
In addition to its retrospective nature, the main limitation of the present study is the fact that we did not routinely measure voriconazole levels. Voriconazole has a nonlinear pharmacokinetic profile with wide inter-and intra-individual variability, and inconsistent absorption and genetic polymorphisms in the isoenzyme CYP2C19, which primarily metabolizes voriconazole. 33, 34 Variations in voriconazole concentrations can affect the CYP3A4 inhibition and result in sirolimus and tacrolimus concentration variations. In addition, the therapeutic window of voriconazole is narrow. 35, 36 Finally, given the fact that most patients were at low risk for IFI, we cannot draw definitive conclusions regarding the efficacy of the antifungal prophylaxis in our study. As noted above, sirolimus itself has been shown to have antifungal activity. The lower risk of IFI in our study was also observed post transplant and was associated with a low incidence of GVHD and a small number of patients requiring systemic steroids. The overall risk of IFI in recipients of allografts at our institution, including patients at higher risk with acute leukemia and aplastic anemia, has historically been 5% (G. Papanicolaou, unpublished). Therefore, the two cases of breakthrough IFI would certainly fall within that range.
This report represents the largest experience to date on the coadministration of sirolimus and voriconazole and supports its feasibility and safety. The empirical dose-reduction strategy and close serum drug monitoring ensured that sirolimus blood concentrations remain within the narrow therapeutic range, reducing toxicity and maximizing efficacy.
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